News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
595,521 Results
Type
Article (35783)
Company Profile (113)
Press Release (559625)
Section
Business (170986)
Career Advice (2697)
Deals (32235)
Drug Delivery (64)
Drug Development (71870)
Employer Resources (155)
FDA (15321)
Job Trends (14427)
News (297093)
Policy (28723)
Tag
Academia (2637)
Africa (748)
Alabama (33)
Allergies (39)
Alliances (42570)
Alzheimer's disease (1125)
Antibody-drug conjugate (ADC) (33)
Approvals (15268)
Arizona (84)
Artificial intelligence (39)
Asia (34869)
Australia (6195)
Bankruptcy (278)
Best Places to Work (11619)
Biosimilars (49)
C2C Services and Suppliers (62337)
California (836)
Canada (639)
Cancer (153)
Career advice (2233)
CAR-T (33)
Cell therapy (65)
China (39)
Clinical research (55795)
Collaboration (47)
Colorado (34)
COVID-19 (2327)
Cystic fibrosis (71)
Diabetes (30)
Diagnostics (6122)
Diversity, equity & inclusion (38)
Drug pricing (43)
Earnings (64275)
Employer resources (131)
Europe (80327)
Events (96497)
Executive appointments (27)
FDA (15363)
Florida (106)
Funding (28)
Gene therapy (48)
GLP-1 (383)
Government (3901)
Healthcare (19516)
Hotbed/Location (409528)
Idaho (56)
Illinois (188)
Indiana (109)
Infectious disease (2338)
Inflammatory bowel disease (88)
Interviews (534)
IPO (15767)
Job creations (2854)
Job search strategy (1877)
Kansas (88)
Layoffs (330)
Legal (6272)
Liver cancer (43)
Lung cancer (31)
Maine (52)
Management (52)
Manufacturing (35)
Maryland (242)
Massachusetts (458)
Medical device (13550)
Medtech (13553)
Mergers & acquisitions (16244)
Metabolic disorders (107)
Neuroscience (1196)
New Jersey (61)
New York (82)
NextGen Class of 2024 (6671)
Non-profit (4784)
North Carolina (175)
Obesity (62)
Opinion (176)
Parkinson's disease (30)
Patents (30)
Peanut (35)
Pennsylvania (55)
People (49778)
Phase I (17279)
Phase II (24783)
Phase III (18570)
Policy (32)
Postmarket research (1999)
Preclinical (7081)
Rare diseases (91)
Real estate (4856)
Recruiting (61)
Regulatory (19226)
Research institute (2418)
Resumes & cover letters (442)
South America (1070)
Startups (3011)
Texas (90)
United States (2986)
Vaccines (359)
Washington State (117)
Weight loss (51)
Date
Today (47)
Last 7 days (495)
Last 30 days (1907)
Last 365 days (39240)
2024 (22095)
2023 (41284)
2022 (52114)
2021 (57042)
2020 (55569)
2019 (48735)
2018 (36630)
2017 (32103)
2016 (30368)
2015 (35474)
2014 (24629)
2013 (19206)
2012 (20726)
2011 (21532)
2010 (18623)
595,521 Results for "bioarctic ab".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
The Nomination Committee’s proposal for the election of Board members and Chairperson of the Board in BioArctic AB
BioArctic AB hereby announces that the Nomination Committee for BioArctic AB presents the following proposals regarding the resolution on the number of board members and the election of board members and Chairperson of the Board at the Annual General Meeting on May 22, 2024.
April 16, 2024
·
4 min read
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
BioArctic AB announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic’s proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidate.
April 20, 2024
·
4 min read
Drug Development
BioArctic: Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contributions to science and treatment of Alzheimer’s disease
BioArctic AB announced that BioArctic’s founder, Professor Lars Lannfelt, was awarded the European Grand Prix for his research on Alzheimer’s disease at the anniversary gala for La Fondation Recherche Alzheimer in Paris on March 18.
March 19, 2024
·
5 min read
BioArctic’s focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm
BioArctic AB’s commitment to its Sustainable Innovation approach - combining scientific progress with responsible business practices and a dedication to environmental, social, and corporate governance principles - has earned the company a place on the new Nasdaq OMX Sweden Small Cap 30 ESG Responsibility Index launched.
April 10, 2024
·
3 min read
BioArctic’s partner Eisai presents updated sales simulation for Leqembi® at its annual press conference
BioArctic AB’s partner Eisai published a presentation including a simulation of potential future sales for Leqembi, the world’s first fully approved disease-modifying treatment for Alzheimer’s disease.
March 7, 2024
·
3 min read
BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress
BioArctic AB announced that the company and its partner Eisai will present new data on lecanemab at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, to be held in Lisbon, Portugal and virtually, March 5-9.
February 29, 2024
·
9 min read
The European Medicines Agency’s Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab: BioArctic
BioArctic AB’s partner Eisai announced that the Scientific Advisory Group will convene to discuss the Marketing Authorisation Application of lecanemab, which is currently under review by the European Medicines Agency.
January 11, 2024
·
6 min read
BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress
BioArctic’s founder, Professor Lars Lannfelt, presented data on the binding properties of the anti-amyloid-beta antibody lecanemab and other anti Aβ antibodies.
March 11, 2024
·
7 min read
Leqembi® (lecanemab) launched in China
BioArctic AB’s partner Eisai announced today that Leqembi® has been launched in China. Leqembi received approval in January 2024 as a treatment of mild cognitive impairment due to Alzheimer’s disease and mild AD dementia.
June 27, 2024
·
7 min read
Business
Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March 2025)
BioArctic AB’s partner Eisai said that they expect Leqembi sales to total JPY 56.5 billion for their fiscal year 2024.
May 15, 2024
·
5 min read
1 of 59,553
Next
